AdvisorNet Financial Inc Sells 419 Shares of Baxter International Inc. (NYSE:BAX)

AdvisorNet Financial Inc lowered its position in shares of Baxter International Inc. (NYSE:BAXGet Rating) by 16.7% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,083 shares of the medical instruments supplier’s stock after selling 419 shares during the period. AdvisorNet Financial Inc’s holdings in Baxter International were worth $134,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Quantitative Investment Management LLC bought a new stake in Baxter International in the 4th quarter worth approximately $1,978,000. Banco de Sabadell S.A grew its position in Baxter International by 16.7% in the 4th quarter. Banco de Sabadell S.A now owns 19,302 shares of the medical instruments supplier’s stock worth $1,658,000 after purchasing an additional 2,759 shares during the period. Altavista Wealth Management Inc. grew its position in Baxter International by 26.3% in the 4th quarter. Altavista Wealth Management Inc. now owns 4,804 shares of the medical instruments supplier’s stock worth $412,000 after purchasing an additional 1,000 shares during the period. Alpha Paradigm Partners LLC bought a new stake in Baxter International in the 4th quarter worth approximately $700,000. Finally, Laurel Wealth Advisors Inc. purchased a new position in shares of Baxter International during the 4th quarter worth $484,000. Institutional investors own 84.69% of the company’s stock.

Baxter International Stock Down 2.0 %

Shares of BAX stock opened at $55.47 on Thursday. The stock has a market cap of $27.94 billion, a P/E ratio of 27.74, a PEG ratio of 2.11 and a beta of 0.60. Baxter International Inc. has a 52 week low of $54.45 and a 52 week high of $89.70. The company has a quick ratio of 1.33, a current ratio of 2.01 and a debt-to-equity ratio of 1.83. The company’s fifty day simple moving average is $60.06 and its two-hundred day simple moving average is $68.63.

Baxter International (NYSE:BAXGet Rating) last announced its quarterly earnings results on Thursday, July 28th. The medical instruments supplier reported $0.87 EPS for the quarter, hitting the consensus estimate of $0.87. The business had revenue of $3.75 billion for the quarter, compared to analysts’ expectations of $3.88 billion. Baxter International had a net margin of 7.12% and a return on equity of 21.75%. The business’s quarterly revenue was up 20.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.80 EPS. Analysts predict that Baxter International Inc. will post 3.63 EPS for the current fiscal year.

Baxter International Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, October 3rd. Stockholders of record on Friday, September 2nd will be issued a $0.29 dividend. The ex-dividend date is Thursday, September 1st. This represents a $1.16 dividend on an annualized basis and a dividend yield of 2.09%. Baxter International’s dividend payout ratio (DPR) is presently 58.00%.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the stock. Deutsche Bank Aktiengesellschaft dropped their price target on shares of Baxter International from $99.00 to $69.00 in a research note on Friday, July 29th. Wells Fargo & Company cut shares of Baxter International from an “overweight” rating to an “equal weight” rating and set a $71.00 price target on the stock. in a research note on Friday, June 24th. Cowen dropped their price target on shares of Baxter International from $95.00 to $70.00 in a research note on Friday, July 29th. JPMorgan Chase & Co. dropped their price target on shares of Baxter International from $90.00 to $78.00 and set an “overweight” rating on the stock in a research note on Friday, June 24th. Finally, Citigroup dropped their price target on shares of Baxter International from $82.00 to $74.00 in a research note on Thursday, July 28th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $77.69.

Baxter International Profile

(Get Rating)

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit.

Featured Articles

Want to see what other hedge funds are holding BAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Baxter International Inc. (NYSE:BAXGet Rating).

Institutional Ownership by Quarter for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.